Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Curasight announces approval of clinical trial application (CTA) for phase 2 trial with uTRACE[®] in prostate cancer patients

· Dosing of first patient expected 2Q 2024 · CTA approval marks progress in development of uTRACE[®] in prostate cancer under the collaboration between Curasight and Curium Inc. · Phase 2 trial is part of Curasight’s efforts to build a pipeline of products using radiopharmaceuticals for improved diagnosis and more targeted treatment of different cancer types  Copenhagen, April 16, 2024 - Curasight A/S (“Curasight” or “the Company” – TICKER: CURAS), a clinical stage radiopharmaceuticals company, today announced approval of clinical trial application (CTA) from the European Medicines

Aker Solutions ASA: Transactions made under the buy-back programme

April 16, 2024 – On February 12, 2024, Aker Solutions ASA (“Aker Solutions”) announced a share buy-back program of up to NOK 500 million, with a maximum of 12.5 million shares, in the period from 12 February 2024 to 31 July 2024.DNB, acting under an irrevocable mandate from Aker Solutions, has carried out the following transactions under the buy-back program: +-------------------------------+---------+-------------+-----------+| Date |Number of| Weighted |Total daily|| | shares |average price|transaction||

Notice to attend the annual general meeting of Minesto AB

The shareholders of Minesto AB (publ), reg. no. 556719-4914 (“Minesto” or the ”Company”), are hereby given notice to attend the Annual General Meeting to be held on Wednesday 22 May 2024 at 10 a.m. at Hotel Riverton at the address Stora Badhusgatan 26 in Gothenburg. The entrance opens and the registration starts at 9.30 a.m.Exercise voting rights at the general meeting Any shareholder wishing to participate at the Annual General Meeting must: (i)                       be entered in the share register kept by Euroclear Sweden AB as per Tuesday 14 May 2024, and, if the shares are

#24-137 Adjustment to warrants with Holmen as underlying due to extraordinary dividend.

The recalculation will be effective from 17[th] of April. Please contact the issuer for detailed information about the recalculation.For more details see attached file. For further information concerning this NGM notice please contact: Listing on listings@ngm.se. Nordic Growth Market NGM AB About NGMNordic Growth Market NGM AB (NGM) is an authorized stock exchange with operations in Sweden, Norway, Denmark and Finland. The exchange is a wholly-owned subsidiary of Boerse Stuttgart, the leading retail exchange in Germany. NGM offers a complete marketplace for exchange traded

ABS Presents at Industry Workshop by Hellenic Ships' Design and Construction Directorate

Dr. Demetres Armanes, ABS Manager, Technology, Engines and Controls Center, presented the applicable ABS Rules, guides, type approvals, technology qualifications and vessels’ classification updates about hybrid and electric vessels, during a workshop in Athens organized by the Hellenic Ships’ Design and Construction Directorate of the Greece Ministry of Maritime Affairs & Insular Policy. During the workshop, the draft of the new national “Regulation for Safe Electrification, Electric Charging, Berthing Surveys, and Certification of Electric and Hybrid Vessels” was presented and

BPC assumes full ownership of Chinese joint venture, renamed BPC Instruments (Zhejiang) Co Ltd

BPC Instruments AB (“BPC” or the “Company”) is delighted to announce the successful completion of the equity transfer of its Chinese Joint Venture, formerly known as BPC Instruments (Haining) Co Ltd. With this transaction, BPC holds sole ownership of the venture, rebranded as BPC Instruments (Zhejiang) Co Ltd. The transition to complete ownership signifies the Chinese Joint Venture's improved revenue growth and market expansion within China over the last four years, positioning BPC for broader opportunities in both Chinese and international markets. Financial consolidation of the joint

Elicera Therapeutics publishes the annual report for 2023

Elicera Therapeutics AB (publ) (“Elicera”), a clinical stage cell and gene therapy company developing next-generation therapies based on oncolytic viruses and CAR T-cells armed with bystander immune activating properties, using the company’s proprietary and commercially available platform iTANK, publishes the annual report for 2023.   Elicera Therapeutics annual report is now available at the webpage https://www.elicera.com.   The Annual General Meeting will be held on May 16th at 1:00 p.m. at the offices of Advokatfirman Delphi (Mäster Samuelsgatan 17 in Stockholm).

Transaction in Own Shares

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION 16 April 2024 REDDE NORTHGATE PLC (“Redde Northgate” or the “Group” or the “Company”)   Transaction in Own Shares   Redde Northgate plc (LSE:REDD) announces that on 16 April 2024 it purchased the following number of its own shares to be held in treasury:   Class of shares :  Ordinary shares of 50p (“shares”)Number of

Diamyd Medical announces preliminary outcome in the company’s rights issue

THIS PRESS RELEASE MAY NOT BE RELEASED, PUBLICATED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, BELARUS, CANADA, HONGKONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SWITZERLAND, THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH SUCH ACTION IN WHOLE OR IN PART, IS SUBJECT TO LEGAL RESTRICTIONS. THIS PRESS RELEASE DOES NOT CONSTITUTE AN OFFER, OR A SOLICITATION OF ANY OFFER, TO BUY OR SUBSCRIBE FOR ANY SECURITIES IN DIAMYD MEDICAL AB IN ANY JURISDICTION. PLEASE REFER TO THE “IMPORTANT INFORMATION” SECTION BELOW. Diamyd Medical AB (publ) (“Diamyd Medical” or the

Kamux Corporation’s share repurchase program has been completed

Kamux Corporation, Stock Exchange Release, 16.4.2024 at 19:00 Kamux Corporation’s share repurchase program has been completed Kamux has completed the share repurchase program as announced on March 20, 2024. During March 21–April 16, 2024 Kamux repurchased in aggregate 135,000 of its own shares at public trading on Nasdaq Helsinki Ltd. for an average price per share of EUR 5.8361. The total purchase price paid for the shares was EUR 787,875.71. The share repurchases were based on the authorization given by the Annual General Meeting of 2023 for the Board of Directors, and the shares

Pihlajalinna Oyj: Acquisition of own shares on April 16, 2024

Pihlajalinna Oyj: Acquisition of own shares on April 16, 2024 Pihlajalinna Oyj’s stock exchange release on April 16, 2024, at 07:00 p.m. EET Date April 16, 2024Exchange transaction BuyShare trading code PIHLISAmount, shares 2,412Average price/share (EUR) 7.9415Total cost (EUR) 19,154.90 After the acquisitions Pihlajalinna Oyj holds a total of 70,619 treasury shares. ON BEHALF OF PIHLAJALINNA OYJ Danske Bank A/S, Finland Branch  Antti Väliaho                        Jonathan Nyberg Additional

Kamux Corporation: Share repurchase 16.4.2024

Kamux Corporation, Stock Exchange Release, 16.4.2024 at 18:30 Kamux Corporation: Share repurchase 16.4.2024 In the Helsinki Stock Exchange Trade date          16.4.2024Bourse trade        BuyShare                 KAMUXAmount            3,339 SharesAverage price/ share   5.7120 EURTotal cost           19,072.37 EUR Kamux Corporation now holds a total of 144,053 shares including the shares repurchased on 16.4.2024.     On behalf of Kamux CorporationNordea Bank Oyj                           Janne Sarvikivi

UNITED BANKERS PLC: ACQUISITION OF OWN SHARES 16.04.2024

United Bankers Plc NOTIFICATION   16.04.2024 at 18:30   UNITED BANKERS PLC: ACQUISITION OF OWN SHARES 16.04.2024   Date 16.04.2024  Exchange transaction Buy  Share class UNITED  Amount 73  Average price/share 16.9000 EURHighest price/share 16.9000 EURLowest price/share 16.9000 EURTotal price 1,233.70   EUR        The shares held by United Bankers Plc on 16.04.2024   UNITED 4,059         On behalf of United

Ferronordic publishes annual and sustainability report for 2023

Ferronordic’s annual and sustainability reports for 2023 has been published and is available on the Company’s website at www.ferronordic.com/investor-relations/reports-and-presentations/     -------------------------------------------------------           About Ferronordic Ferronordic is a service and sales company in the areas of trucks and construction equipment. It is dealer of Volvo Trucks, Renault Trucks and Sandvik Mobile crushers and screens in Germany. Ferronordic is the dealer for Volvo CE in all or parts of nine states in the United States and also

Prostatype Genomics announces strong positive final results from multicentre study with Prostatype® in Spain

Prostatype Genomics (”Prostatype Genomics” or ”the Company”) announces that the retrospective multicentre study in Spain with the Company’s gene test Prostatype®, which includes 126 patients with prostate cancer at seven hospitals and is coordinated by the Spanish National Urology Association, has now been completed with strong positive results. The final results show that the treatment plan could have been modified for 39% of the patients if Prostatype® had been used as a decision basis at the time of diagnosis. Prostatype® was launched in Spain in 2023, and Prostatype Genomics now see good

Holmen 2024 Annual General Meeting

A total dividend of SEK 11.50 per share was approved at Holmen’s Annual General Meeting.Financial statements for the financial year 2023, dividend, etc.The AGM adopted the income statement and balance sheet for the parent company and the Group for the financial year 2023 and resolved to pay a dividend of SEK 11.50 per share. The dividend record date was confirmed as 18 April 2024. Given this record date, the dividend is expected to be paid on 23 April 2024. Board, auditor and feesThe AGM resolved to discharge the members of the Board and the CEO from liability. The AGM resolved

The English edition of Bravida's Annual and Sustainability Report 2023 is published

Bravida Holding AB’s Annual and Sustainability Report 2023 is now published in English and is available at the corporate website.“2023 was an exciting and challenging year for Bravida. Despite it being a difficult market, we are relatively stable. We are an enabler regarding the climate transition and ensure that what needs to work works, regardless of the economic cycle and global situation”, comments Mattias Johansson, CEO and Group President, Bravida. Read more in the English edition of Bravida's Annual and Sustainability Report 2023, which can be found via the following link:

#24-136 Delisting of Derivatives from NGM

Information about certain derivatives that will be delisted from NGM.For more details, see attached files. For further information concerning this NGM notice please contact NGM Listing department on listings@ngm.se. Nordic Growth Market NGM AB About NGMNordic Growth Market NGM AB (NGM) is an authorized stock exchange with operations in Sweden, Norway, Denmark and Finland. The exchange is a wholly-owned subsidiary of Boerse Stuttgart, the leading retail exchange in Germany. NGM offers a complete marketplace for exchange traded products and provides a complete platform for

There are no items matching the current filter
There are no more items matching the current filter
Back to top